- Home
- CHY vs NTLA Comparison
CHY vs NTLA Comparison
Compare CHY & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- NTLA
- Stock Information
- Founded
- CHY 2003
- NTLA 2014
- Country
- CHY United States
- NTLA United States
- Employees
- CHY N/A
- NTLA N/A
- Industry
- CHY Investment Managers
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CHY Finance
- NTLA Health Care
- Exchange
- CHY Nasdaq
- NTLA Nasdaq
- Market Cap
- CHY 934.9M
- NTLA 959.4M
- IPO Year
- CHY N/A
- NTLA 2016
- Fundamental
- Price
- CHY $11.32
- NTLA $9.53
- Analyst Decision
- CHY
- NTLA Buy
- Analyst Count
- CHY 0
- NTLA 18
- Target Price
- CHY N/A
- NTLA $50.53
- AVG Volume (30 Days)
- CHY 128.3K
- NTLA 3.2M
- Earning Date
- CHY 01-01-0001
- NTLA 02-20-2025
- Dividend Yield
- CHY 10.11%
- NTLA N/A
- EPS Growth
- CHY N/A
- NTLA N/A
- EPS
- CHY N/A
- NTLA N/A
- Revenue
- CHY N/A
- NTLA $43,086,000.00
- Revenue This Year
- CHY N/A
- NTLA $50.68
- Revenue Next Year
- CHY N/A
- NTLA N/A
- P/E Ratio
- CHY N/A
- NTLA N/A
- Revenue Growth
- CHY N/A
- NTLA N/A
- 52 Week Low
- CHY $9.97
- NTLA $9.25
- 52 Week High
- CHY $12.16
- NTLA $34.87
- Technical
- Relative Strength Index (RSI)
- CHY 37.42
- NTLA 36.07
- Support Level
- CHY $11.07
- NTLA $9.93
- Resistance Level
- CHY $11.48
- NTLA $10.73
- Average True Range (ATR)
- CHY 0.19
- NTLA 0.66
- MACD
- CHY 0.00
- NTLA 0.08
- Stochastic Oscillator
- CHY 30.77
- NTLA 13.12
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high yield securities.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.